Edition:
United Kingdom

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

93.99USD
23 Jan 2018
Change (% chg)

$0.55 (+0.59%)
Prev Close
$93.44
Open
$92.66
Day's High
$94.17
Day's Low
$92.38
Volume
230,098
Avg. Vol
326,197
52-wk High
$94.17
52-wk Low
$63.69

Latest Key Developments (Source: Significant Developments)

Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT HAS AN INITIAL TERM OF THREE YEARS.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT PROVIDES THAT RÖHRHOFF WILL BE ENTITLED TO AN ANNUAL BASE SALARY OF EUR 850,000.PERRIGO COMPANY PLC - RÖHRHOFF WILL ALSO RECEIVE A EUR 850,000 SIGN-ON BONUS, TO BE PAID EUR 425,000 IN CASH AND EUR 425,000 IN RSUS.PERRIGO SAYS RÖHRHOFF TO BE ENTITLED TO TARGET ANNUAL BONUS OPPORTUNITY OF NO LESS THAN 125% OF ANNUAL BASE SALARY- SEC FILING.  Full Article

Perrigo appoints Uwe Röhrhoff as CEO
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER.PERRIGO COMPANY- ‍ANNOUNCED APPOINTMENT OF UWE RÖHRHOFF AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 15, 2018, FOLLOWING RETIREMENT OF JOHN T. HENDRICKSON​.‍JOHN T. HENDRICKSON TO REMAIN WITH COMPANY UNTIL MARCH 15, 2018 TO ENSURE SUCCESSFUL TRANSITION​.  Full Article

Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07%
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Perrigo Company Plc ::PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF PROLENSA® OPHTHALMIC SOLUTION 0.07%.  Full Article

Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY PLC - ‍LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II​.  Full Article

Perrigo Company completes divestiture of API business for $110 million
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Perrigo Company PLC :Perrigo Company completes divestiture of API business for $110 million.  Full Article

Perrigo Q3 GAAP EPS $0.31
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Perrigo Company PLC :Perrigo Company PLC reports third quarter 2017 financial results.Q3 sales $1.2 billion versus I/B/E/S view $1.17 billion.Sees FY 2017 adjusted earnings per share $4.80 to $4.95.Sees FY 2017 earnings per share $0.74 to $0.89.Q3 adjusted earnings per share $1.39 excluding items.Q3 gaap earnings per share $0.31.Q3 earnings per share view $1.11 -- Thomson Reuters I/B/E/S.  Full Article

Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel 0.05 pct
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Perrigo Company Plc :Perrigo announces tentative fda approval for a first-to-file generic version of Picato Gel 0.05 pct.‍Received tentative approval from FDA for generic version of Picato Gel 0.05 pct​.  Full Article

Perrigo announces patent litigation settlement for generic version of Onexton® Gel
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Perrigo Company Plc :Perrigo announces patent litigation settlement for the generic version of Onexton® Gel.Perrigo Company Plc - ‍details of settlement are confidential​.Perrigo Company Plc - ‍settled Hatch-Waxman litigation relating to Onexton Gel ​.Perrigo Company - settled ‍litigation relating to Onexton Gel brought by Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences​.  Full Article

Perrigo announces tentative FDA approval for generic version of Picato gel.015%
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Perrigo Company Plc :Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel .015%.‍RPT-Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel .015%​.  Full Article

Perrigo says Rx segment, year-over-year price erosion assumption remains at 9 pct to 11 pct
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Perrigo Company Plc :Perrigo says Rx segment, year-over-year price erosion assumption remains at 9 percent to 11 percent - Conf Call.Perrigo says expected net sales forecast increased in the Rx segment to nearly $900 million due to earlier than expected launch of new products.  Full Article

Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg

ZURICH Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.